These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29657613)

  • 21. High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study.
    van Gennep S; Evers SW; Rietdijk ST; Gielen ME; de Boer NKH; Gecse KB; Ponsioen CIJ; Duijvestein M; D'Haens GR; de Boer AGEM; Löwenberg M
    Inflamm Bowel Dis; 2021 Feb; 27(3):352-363. PubMed ID: 32378704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
    Buono JL; Carson RT; Flores NM
    Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect costs and public finance consequences of heart failure in Poland, 2012-2015.
    Łyszczarz B
    BMC Public Health; 2018 Sep; 18(1):1130. PubMed ID: 30231932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
    Travis S; Feagan BG; Peyrin-Biroulet L; Panaccione R; Danese S; Lazar A; Robinson AM; Petersson J; Pappalardo BL; Bereswill M; Chen N; Wang S; Skup M; Thakkar RB; Chao J
    J Crohns Colitis; 2017 Oct; 11(11):1317-1325. PubMed ID: 28981846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis.
    Villacorta R; Teeple A; Lee S; Fakharzadeh S; Lucas J; McElligott S
    Br J Dermatol; 2020 Sep; 183(3):548-558. PubMed ID: 31840228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study.
    Vaizey CJ; Gibson PR; Black CM; Nicholls RJ; Weston AR; Gaya DR; Sebastian S; Shaw I; Lewis S; Bloom S; Gordon JN; Beale A; Arnott I; Campbell S; Fan T
    Frontline Gastroenterol; 2014 Jul; 5(3):183-189. PubMed ID: 28839768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    Armuzzi A; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Salese L; daCosta DiBonaventura M
    BMC Gastroenterol; 2020 Jan; 20(1):18. PubMed ID: 31964359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland.
    Malinowski KP; Kawalec PP; Moćko P
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):295-303. PubMed ID: 26377953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial.
    Connolly MP; Nielsen SK; Currie CJ; Marteau P; Probert CS; Travis SP
    J Crohns Colitis; 2009 Sep; 3(3):168-74. PubMed ID: 21172266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study.
    Gáspár K; Hunor Gergely L; Jenei B; Wikonkál N; Kinyó Á; Szegedi A; Remenyik É; Kiss N; Jin X; Sárdy M; Beretzky Z; Péntek M; Gulácsi L; Bánvölgyi A; Brodszky V; Rencz F
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):399-408. PubMed ID: 33629618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe.
    Kotseva K; Gerlier L; Sidelnikov E; Kutikova L; Lamotte M; Amarenco P; Annemans L
    Eur J Prev Cardiol; 2019 Jul; 26(11):1150-1157. PubMed ID: 30955367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
    Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
    J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect costs and incidence of caregivers' short-term absenteeism in Poland, 2006-2016.
    Łyszczarz B
    BMC Public Health; 2019 May; 19(1):598. PubMed ID: 31101035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA.
    Braakman-Jansen LM; Taal E; Kuper IH; van de Laar MA
    Rheumatology (Oxford); 2012 Feb; 51(2):354-61. PubMed ID: 22179729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
    Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
    J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review.
    Kawalec P
    Arch Med Sci; 2016 Apr; 12(2):295-302. PubMed ID: 27186172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1319-1325. PubMed ID: 27497991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe.
    Ruiz-Casas L; Evans J; Rose A; Pedra GG; Lobo A; Finnegan A; Hayee B; Peyrin-Biroulet L; Sturm A; Burisch J; Terry H; Avedano L; Tucknott S; Fiorino G; Limdi J
    BMC Gastroenterol; 2021 Dec; 21(1):456. PubMed ID: 34863112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic and social cost of epilepsy in Poland: 5-year analysis.
    Jędrzejczak J; Majkowska-Zwolińska B; Chudzicka-Bator A; Żerda I; Władysiuk M; Godman B
    Eur J Health Econ; 2021 Apr; 22(3):485-497. PubMed ID: 33582892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.